Department of Internal Medicine, Kocaeli University School of Medicine, Kocaeli, Turkey.
Department of Pathology, Kocaeli University School of Medicine, Kocaeli, Turkey.
J Investig Med. 2024 Dec;72(8):848-856. doi: 10.1177/10815589241270543. Epub 2024 Aug 28.
The A disintegrin and metalloprotease (ADAM) family is involved in many vital cellular events, from proliferation to migration, and accumulated evidence suggests its increased expression in malignant tumors. In this study, we investigated ADAM17 expression in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological factors and survival. Immunohistochemical staining of ADAM expression was performed in 108 patients with NSCLC and in 54 control cases with no known malignant diagnosis. Association between ADAM17 expression, clinicopathological factors, and survival were analyzed. The Kaplan-Meier method was used for survival analysis. ADAM17 was lowly expressed in 89 (82.4%) and highly expressed in 19 (17.6%) of the patients with NSCLC. In univariate analysis, high ADAM17 expression, lymphovascular invasion, stage, and treatment response significantly affected progression-free survival (PFS) and overall survival (OS) (p < 0.05). Multivariate analysis also showed that high ADAM17 expression, lymphovascular invasion, stage, and treatment response were important prognostic factors for PFS and OS (p < 0.05). Our study revealed that high ADAM17 expression significantly associated with OS and PFS in patients with NSCLC. ADAM17 may potentially be the area of a new targeted treatment strategy in NSCLC. Thus, routine evaluation of ADAM17 expression in patients with NSCLC may be a future consideration.
解整合素金属蛋白酶（ADAM）家族参与许多重要的细胞事件，从增殖到迁移，越来越多的证据表明其在恶性肿瘤中的表达增加。在这项研究中，我们研究了 ADAM17 在非小细胞肺癌（NSCLC）中的表达及其与临床病理因素和生存的关系。对 108 例 NSCLC 患者和 54 例无恶性诊断的对照病例进行了 ADAM 表达的免疫组织化学染色。分析了 ADAM17 表达与临床病理因素和生存之间的关系。采用 Kaplan-Meier 法进行生存分析。在 NSCLC 患者中，ADAM17 低表达 89 例（82.4%），高表达 19 例（17.6%）。单因素分析表明，ADAM17 高表达、血管淋巴管浸润、分期和治疗反应显著影响无进展生存期（PFS）和总生存期（OS）（p<0.05）。多因素分析也表明，ADAM17 高表达、血管淋巴管浸润、分期和治疗反应是 PFS 和 OS 的重要预后因素（p<0.05）。我们的研究表明，ADAM17 高表达与 NSCLC 患者的 OS 和 PFS 显著相关。ADAM17 可能是 NSCLC 新靶向治疗策略的潜在靶点。因此，常规评估 NSCLC 患者的 ADAM17 表达可能是未来的考虑因素。
